- INSTRUMENTO Coinversión en Startups con Organizaciones de Capital Emprendedor e Inversores Ángeles
- BENEFICIARIO Fernando Slamovitz : Yeda
- DEPARTAMENTO Montevideo
- PRÉSTAMO USD 150000
- FECHA DE INICIO 24.03.2025
- DURACIÓN 12 meses
- AÑO CONVOCATORIA 2025
- CÓDIGO MF_UIH_2025_2_185581
- FASE CERRADO
- ESTADO Repago
Yeda is a personalized medicine startup that helps users prevent abrupt glycemic variations and address metabolic conditions such as type 2 diabetes, overweight, and obesity by leveraging artificial intelligence and gut microbiome insights to predict personalized glycemic responses to every meal. It is inspired by successful models like Zoe, Levels, Veri, January.ai and NutriSense, yet tailored to meet the unique needs of the LATAM market, starting in Brazil. Our first product is an app that integrates dietary logs, continuous glucose monitoring, and bioimpedance tracking to deliver real-time, personalized dietary recommendations. This empowers users to make practical adjustments that stabilize glucose levels and enhance overall health. One of our main items of defensibility is the region-specific dataset and the predictor trained with it. This innovation is complemented by strategic partnerships for validation and distribution, ensuring Yeda?s solutions are both cutting-edge and deeply relevant to the LATAM context. Targeting individuals aged 35?65 invested in their metabolic health, Yeda serves private health patients and gym-goers seeking technology-driven, personalized solutions for disease prevention, weight management and well-being enhancement. Yeda operates under a B2B SaaS model, providing private clinics with access to efficient tools for metabolic health management?an unmet need in LATAM. To lead the trend regionally, Yeda strategically positions itself within major channels that enable efficient and rapid distribution. In Brazil, its partnerships with Hospital Albert Einstein in the healthcare segment and N2B (SmartFit) in the wellness segment lay the groundwork for exponential growth, which can be replicated in other territories. As the adoption of personalized health solutions accelerates globally and treatments like Ozempic revolutionize metabolic care, Yeda is perfectly positioned to complement these trends, creating a unique opportunity to lead LATAM into the new era of precision-driven, AI-powered healthcare.